baricitinib

inhibits Janus kinases JAK1 and JAK2

Also Known As:

3-azetidineacetonitrile, 1-(ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)-; 3-azetidineacetonitrile, 1-(ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)-, phosphate (1:1); INCB-028050; INCB-28050; INCB028050; LY-3009104; LY3009104; Olumiant; baricitinib phosphate; baricitinib phosphate salt

Networked: 859 relevant articles (146 outcomes, 252 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Tanaka, Yoshiya: 26 articles (05/2022 - 03/2016)
2.	de Bono, Stephanie: 20 articles (01/2022 - 03/2016)
3.	Smolen, Josef S: 19 articles (01/2022 - 01/2014)
4.	DeLozier, Amy M: 18 articles (07/2022 - 01/2017)
5.	Taylor, Peter C: 17 articles (09/2022 - 02/2015)
6.	Takeuchi, Tsutomu: 15 articles (01/2022 - 01/2017)
7.	Rooney, Terence: 15 articles (01/2020 - 03/2016)
8.	Schlichting, Douglas E: 14 articles (03/2022 - 02/2015)
9.	de la Torre, Inmaculada: 13 articles (05/2022 - 01/2017)
10.	Emery, Paul: 13 articles (01/2021 - 01/2017)

Related Diseases

1.	COVID-19 09/01/2022 - "Baricitinib proves to be a safe and effective treatment for COVID-19. Administered as monotherapy or in conjunction with other drugs, baricitinib provides tremendous clinical benefit to infected patients and shows good potential in terms of efficacy for future COVID-19 regimens." 07/01/2022 - "In hospitalised patients with COVID-19, baricitinib was associated with reduced 28-day mortality although there was not a statistically significant reduction in progression to IMV or ECMO. " 09/01/2023 - "Pharmacokinetics and dialytic clearance of baricitinib during in vivo continuous venovenous haemodialysis in a patient with COVID-19." 10/01/2022 - "The aim of the current systematic review and meta-analysis was to evaluate the efficacy of baricitinib in COVID-19 patients. " 07/01/2022 - "Baricitinib used in conjunction with standard of care treatments is associated with improved mortality in hospitalised patients with COVID-19 disease. "
2.	Rheumatoid Arthritis 01/01/2021 - "Rapid Onset of Efficacy of Baricitinib in Chinese Patients with Moderate to Severe Rheumatoid Arthritis: Results from Study RA-BALANCE." 12/01/2018 - "Baricitinib is an orally administered inhibitor of JAK1 and JAK2 that has been shown to be effective in treating rheumatoid arthritis (RA). " 06/01/2021 - "Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2 mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled Studies and One Long-Term Extension Study." 01/01/2021 - "Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study." 12/14/2020 - "This study aimed to evaluate the short-term effectiveness and safety profiles of baricitinib and explore factors associated with improved short-term effectiveness in patients with rheumatoid arthritis (RA) in clinical settings. "
3.	Atopic Dermatitis (Atopic Eczema) 10/01/2023 - "Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3." 12/01/2023 - "Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial." 05/01/2023 - "Baricitinib demonstrated efficacy in treating adults with moderate-to-severe atopic dermatitis (AD) in Phase 3 clinical trials. " 12/01/2022 - "To address the need for long-term efficacy and patient-reported outcomes (PROs) data for patients with atopic dermatitis (AD) treated with baricitinib 2 mg, a study was conducted to evaluate the efficacy of baricitinib 2 mg in adult patients with moderate-to-severe AD. " 06/01/2021 - "Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials."
4.	Alopecia Areata 07/01/2023 - "While longer-term data will be necessary to more fully understand the benefits and risks of the drug, currently available data suggest that baricitinib is a useful treatment for patients with severe alopecia areata. " 11/01/2023 - "Baricitinib is effective in treating patients with alopecia areata, particularly for the patchy phenotype, but with a risk of relapse after discontinuation. " 07/01/2023 - "While longer-term data will be of interest, baricitinib appears to be a useful treatment for patients with severe alopecia areata." 12/01/2023 - "Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2." 11/16/2023 - "When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials."
5.	Pain (Aches) 01/01/2022 - "Patients treated with baricitinib reported significantly greater and more rapid pain relief, more weeks with limited to no pain, and clinically meaningful improvements in physical health than patients treated with MTX alone over 1 year." 09/05/2019 - "The proportions of patients in remission or low disease activity with minimal or no pain and with normalised physical function were numerically greater with baricitinib than placebo. " 10/01/2021 - "Baricitinib improved patient-reported skin pain severity as early as day 2. " 07/01/2022 - "Patients with moderate-to-severe AD, treated with baricitinib, reported rapid improvements in skin pain severity by day 1 for baricitinib 2 mg and day 2 for baricitinib 1 mg and remained effective through 16 weeks of treatment, which positively impacted patient QoL." 07/01/2022 - "Skin Pain NRS improvement was significant versus placebo by day 1 baricitinib 2 mg (least squares mean [LSM] difference -4.4%, P = .048) and by day 2 for baricitinib 1 mg (-6.7%, P = .011). "

Related Drugs and Biologics

1.	Janus Kinase Inhibitors
2.	remdesivir
3.	tofacitinib
4.	Janus Kinases
5.	tocilizumab (atlizumab)
6.	Dexamethasone (Maxidex)
7.	Antirheumatic Agents (DMARD)
8.	Janus Kinase 1
9.	Methotrexate (Mexate)
10.	Adalimumab (Humira)

Related Therapies and Procedures

1.	Therapeutics
2.	Noninvasive Ventilation
3.	Artificial Respiration (Mechanical Ventilation)
4.	Aftercare (After-Treatment)
5.	Immunomodulation